Treatment of hirsutism: Comparisons between different antiandrogens with central and peripheral effects

Fertility and Sterility

Volumn 71, Issue 3, 1999, Pages 445-451

  Fruzzetti, Franca ^a   Bersi, Chiara ^a   Parrini, Donatella ^a   Ricci, Cabiria ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antiandrogens; Hirsutism; Hyperandrogenism

Indexed keywords

ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; CYPROTERONE ACETATE; DIANE; FINASTERIDE; FLUTAMIDE; TESTOSTERONE;

ADOLESCENT; ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HIRSUTISM; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; FEMALE; FINASTERIDE; FLUTAMIDE; HIRSUTISM; HORMONES; HUMANS; HYPERANDROGENISM;

EID: 0032942176     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00486-5     Document Type: Article

References (31)

1. Toscano V. Hirsutism pilosebaceous unit dysregulation. Role of peripheral and glandular factors . J Endocrinol Invest. 14:1991;153-170.
2. Mowszowicz I., Melanitou E., Doukani F., Kuttenn F., Mauvais-Jarvis P. Androgen binding capacity and 5α-reductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab. 56:1983;1209-1213.
3. Jenkins E.P., Andersson S., Imperato-McGinley J., Wilson J.D., Russell D.W. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest. 89:1992;293-300.
4. Andersson S., Berman D.M., Jenkins E.P., Russell J., Russell D.W. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature. 354:1992;159-161.
5. Siiteri P.K., Wilson J.D. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in hypertrophic prostate of man. J Clin Invest. 49:1970;1737-1745.
6. Belisle S., Love E.J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism results of a multicentered Canadian study . Fertil Steril. 46:1986;1015-1020.
7. Dorfman R.I. Biological activity of antiandrogens. Br J Dermatol. 82:(Suppl 6):1970;3-8.
8. Hammerstein J., Cupceancu B. Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wochenschr. 94:1969;829-834.
9. Sogani P.C., Vagaiwala M.R., Whitmore W.F. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer. 54:1984;744-750.
10. Cusan L., Dupont A., Belanger A., Tremblay R.R., Mahes G., Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol. 23:1990;462-469.
11. Rittmaster R.S. Finasteride. N Engl J Med. 330:1990;120-125.
12. Fruzzetti F., De Lorenzo D., Parrini D., Ricci C. Effects of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab. 79:1994;831-835.
13. Serafini P., Ablan F., Lobo R.A. 5α-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab. 60:1983;349-355.
14. Miles R.A., Cassidenti D.L., Carmina E., Gentzschein E., Stanczyk F.Z., Lobo R.A. Cutaneous application of an androstenedione gel as an in vivo test of 5α-reductase activity in women. Fertil Steril. 58:1992;708-712.
15. Moghetti P., Castello R., Magnani C.M., Tosi F., Negri C., Armanini D., et al. Clinical and hormonal effects of 5α-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab. 79:1994;1115-1121.
16. Erenus M., Gurbuz O., Durmusoglu F., Dermircay Z., Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil Steril. 61:1994;613-616.
17. Grigoriou O., Papadis C., Konidaris S., Antoniou G., Karikitsos P., Giannikos L. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism a randomized controlled trial . Gynecol Endocrinol. 10:1996;119-123.
18. Falsetti L., Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 42:1990;611-619.
19. Barth J.H., Cherry C.A., Wojanarowska F., Dawber R.P.R. Cyproterone acetate for severe hirsutism results of a double-blind dose-ranging study . Clin Endocrinol (Oxf). 35:1991;5-10.
20. Ciotta L., Cianci A., Marletta E., Pisani L., Agliano A., Palumbo G. Treatment of hirsutism with flutamide and low-dosage oral contraceptive in polycystic ovarian disease patients. Fertil Steril. 62:1994;1129-1135.
21. Couzinet B., Pholsena M., Young J., Schaison G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol (Oxf). 39:1993;157-162.
22. Marugo M., Bernasconi D., Meozzi M., Del Monte P., Zino V., Primarolo P., et al. The use of flutamide in the management of hirsutism. J Endocrinol Invest. 17:1994;195-199.
23. Fruzzetti F., De Lorenzo D., Ricci C., Fioretti P. Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil Steril. 60:1993;806-813.
24. Tolino A., Petrone A., Sarnacchiaro F., Cirillo D., Ronsini S., Lombardi G., et al. Finasteride in the treatment of hirsutism new therapeutical perspectives . Fertil Steril. 66:1996;661-665.
25. Castello R., Tosi F., Perrone F., Negri C., Muggeo M., Moghetti P. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up . Fertil Steril. 66:1996;734-740.
26. Pucci E., Genazzani A.D., Monzani F., Lippi F., Angelini F., Gargani M., et al. Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol Endocrinol. 9:1995;221-228.
27. Wong I.L., Morris R.S., Chang L., Spahn M.A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 80:1995;233-238.
28. Motta T., Maggi G., Pera M., Azzolari E., Casazza S., D'Alberton A. Flutamide in the treatment of hirsutism. Int J Gynaecol Obstet. 36:1991;155-157.
29. Muderris I.I., Bayram F., Sabin Y., Kelestimur F., Tutus A., Ayata D. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil Steril. 66:1996;220-222.
30. Rubens R. Androgen levels during cyproterone acetate and ethinylestradiol treatment of hirsutism. Clin Endocrinol (Oxf). 20:1984;313-325.
31. Ancién P., Mauri M., Gutierrez M. Clinical and hormonal effects of the combination gonadotropin-releasing hormone agonist plus oral contraceptive pills containing ethinylestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenism. Hum Reprod. 12:1997;423-429.